Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Karen Marie Johnson, a director at Oncology Institute, Inc. (NASDAQ:TOI), has acquired a significant number of shares in the company, according to a recent SEC filing. On March 26, Johnson purchased 36,224 shares of common stock at a price of $1.0417 per share, totaling approximately $37,734. The stock, currently trading at $1.14, has shown remarkable momentum with a 258% gain over the past six months. According to InvestingPro analysis, the company appears undervalued against its Fair Value estimate.
The acquisition was part of a private placement transaction directly from the company, as detailed in a Securities Purchase Agreement dated March 24, 2025. This agreement included the issuance of private placement units, each consisting of two shares of the company’s common stock and a common warrant to purchase one share of common stock.
Additionally, Johnson acquired 18,112 common warrants at a cost of $0.1250 per warrant. These warrants are exercisable until March 26, 2030, but are subject to a limitation that prevents the exercise of any portion that would result in beneficial ownership exceeding 4.99% of the company’s outstanding common stock.
Following these transactions, Johnson holds a total of 203,409 shares of Oncology Institute’s common stock. The company maintains strong liquidity with a current ratio of 2.15, while delivering robust revenue growth of 21% in the last twelve months.
In other recent news, The Oncology Institute reported its Q4 2024 earnings, revealing a net loss and missing both earnings per share and revenue forecasts. The company recorded an EPS of -$0.14, which was below the expected -$0.08, and revenue came in at $100.3 million, falling short of the anticipated $109.15 million. Despite this, the Oncology Institute highlighted strategic growth initiatives, such as expansion into Florida and new service contracts, which contributed to a positive cash flow from operations in Q4. The company also reported a 17% year-over-year increase in Q4 revenue, reaching $100.3 million, and a full-year revenue of $393 million, a 21.3% rise from 2023. However, the full-year gross profit decreased by 9.4% to $54 million, and the net loss was $64.6 million, an improvement of $18.4 million from the previous year. Looking ahead, the Oncology Institute projects 2025 revenue between $460 million and $480 million, with expectations to achieve profitability by Q4 2025. In analyst notes, B. Riley’s Yuan Zhi inquired about the company’s growth drivers for 2025, while Noble Capital Markets’ Robert Laboyre sought details on revenue expectations for various segments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.